2096.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:44):

Stats
Today's Volume	3.47M
Average Volume	4.89M
Market Cap	13.49B
EPS	HKD0 ( 2024-03-28 )
Last Dividend	HKD0.176 ( 2023-06-19 )
Next Dividend	HKD0 ( N/A )
P/E	17.83
ATR14	HKD0.00900 (0.17%)

Volume Correlation

Long: 0.14 (neutral)

Short: 0.42 (neutral)

Signal:(57.455) Neutral

Simcere Pharmaceutical Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Simcere Pharmaceutical Correlation - Currency/Commodity

-0.04
( neutral )

-0.37
( neutral )

0.00
( neutral )

0.03
( neutral )

0.00
( neutral )

-0.16
( neutral )

Simcere Pharmaceutical Financials

Annual	2023
Revenue:	HKD0
Gross Profit:	HKD0 (0.00 %)
EPS:	HKD0

Q2	2023
Revenue:	HKD1.69B
Gross Profit:	HKD1.28B (75.79 %)
EPS:	HKD0.430

Q1	2023
Revenue:	HKD1.69B
Gross Profit:	HKD1.28B (75.79 %)
EPS:	HKD0.430

Q4	2022
Revenue:	HKD1.81B
Gross Profit:	HKD1.43B (78.87 %)
EPS:	HKD0.170

Financial Reports:

No articles found.

Simcere Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.176 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Simcere Pharmaceutical Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.35 - good (93.51%) | Divividend Growth Potential Score: 5.33 - Stable (6.69%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.180	2021-06-29
Last Dividend	HKD0.176	2023-06-19
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	HKD0.532	--
Avg. Dividend % Per Year	0.00%	--
Score	2.73	--
Div. Sustainability Score	9.35
Div.Growth Potential Score	5.33
Div. Directional Score	7.34	--

Next Divdend (Est)
(2025-03-31)

HKD0.176 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

2.73

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
3709.HK	Ex Dividend Junior	2023-06-14	Annually	0.00%
1666.HK	Ex Dividend Knight	2023-06-19	Annually	0.00%
0709.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
2219.HK	Ex Dividend Junior	2023-06-12	Annually	0.00%
1234.HK	Ex Dividend Knight	2023-09-05	Semi-Annually	0.00%
0305.HK	Ex Dividend Junior	2023-06-15	Annually	0.00%
3988.HK	Ex Dividend Junior	2023-07-06	Annually	0.00%
1798.HK	Ex Dividend Junior	2023-07-06	Sporadic	0.00%
0831.HK	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
0002.HK	Ex Dividend Knight	2023-09-04	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.522	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.213	1.200	2.88	3.46	[0 - 0.3]
returnOnEquityTTM	0.322	1.500	7.53	10.00	[0.1 - 1]
payoutRatioTTM	0.0722	-1.000	9.28	-9.28	[0 - 1]
currentRatioTTM	2.35	0.800	3.25	2.60	[1 - 3]
quickRatioTTM	1.934	0.800	3.33	2.66	[0.8 - 2.5]
cashRatioTTM	0.976	1.500	5.69	8.53	[0.2 - 2]
debtRatioTTM	0.0911	-1.500	8.48	-10.00	[0 - 0.6]
interestCoverageTTM	-1.800	1.000	-1.778	-1.778	[3 - 30]
operatingCashFlowPerShareTTM	0.0956	2.00	9.97	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.0308	2.00	9.98	10.00	[0 - 20]
debtEquityRatioTTM	0.128	-1.500	9.49	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.769	1.000	0.522	0.522	[0.2 - 0.8]
operatingProfitMarginTTM	0.0911	1.000	-0.177	-0.177	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.219	1.000	9.90	9.90	[0.2 - 2]
assetTurnoverTTM	0.409	0.800	-0.607	-0.486	[0.5 - 2]
Total Score				9.35

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.68	1.000	9.63	0	[1 - 100]
returnOnEquityTTM	0.322	2.50	8.41	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0308	2.00	9.99	10.00	[0 - 30]
dividendYielPercentageTTM	3.67	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0956	2.00	9.97	10.00	[0 - 30]
payoutRatioTTM	0.0722	1.500	9.28	-9.28	[0 - 1]
pegRatioTTM	0	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0487	1.000	-1.282	0	[0.1 - 0.5]
Total Score				5.33

Simcere Pharmaceutical

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. The company's principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Softan, a rosuvastatin calcium tablet; ZAILIN, an amoxicillin granules/dispersible tablet/capsule; Iremod, an iguratimod tablet; Antine, a diclofenac sodium sustained release capsule/gel; and Orencia, an abatacept injection. It also offers promotion services for pharmaceutical products. Simcere Pharmaceutical Group Limited has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize medicines targeting the neurotoxicity amyloid protein N3pE (pGlu-Aß) to treat Alzheimer's disease. The company was founded in 1995 and is headquartered in Nanjing, China.